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Cellular immune responses to melanoma are tightly
regulated and include speci®c T cell responses to self
antigens such as Mart-1 and gp100. Thus, additional
signals apart from those mediated by the T cell
receptor are needed to ensure T cell activation.
Recently, the stress inducible major histocompatibil-
ity complex molecules, MHC class I related chain,
were identi®ed as an activator of both natural killer
and T cells via interaction with their receptor
NKG2D. Herein, we report the expression of MIC in
31 of 40 primary cutaneous melanomas and in 13 of
20 metastatic lesions. Moreover, lymphocytes in®l-
trating the tumor were found to express NKG2D.
Detailed analysis identi®ed both CD3+ T cells as well
as CD56+ natural killer cells contributing to this
NKG2D+ tumor in®ltrating lymphocyte population
present. Key words: T cell/NK cell/T cell receptor/MHC
class I molecule. J Invest Dermatol 118:600±605, 2002
I
mmunologic destruction of tumors is mediated primarily by
lymphocytes (thor Straten et al, 1999). Using anti-tumor
speci®c cytotoxic T cell clones as detectors for immunogenic
tumor-derived determinants bound to the major histocom-
patibility complex (MHC) molecule, several investigators
have shown that T cells recognize peptides derived from
endogenous proteins (Tsai et al, 1997). For melanoma these
proteins fall into three categories: antigens encoded by mutated
genes, antigens encoded by genes that are speci®cally expressed in
tumors and melanocytic differentiation antigens. Melanocytic
differentiation antigens are the products of normal genes, and four
of these antigens, i.e., Melan-A/MART-1, gp100, tyrosinase, and
TRP-2, are also expressed by healthy melanocytes (Kirkin et al,
1998). Hence, there is no special group of proteins that can be
dubbed tumor antigens, and the distinction between self and tumor
antigens is not as strict as previously anticipated. This notion as well
as the recent detection of identical T cell clones in areas of anti-self
and anti-tumor immunity raises the question how the immune
system induces a T cell response against self proteins despite the
powerful mechanisms guarding self tolerance and homeostasis
(Becker et al, 1999; Sherman et al, 2000). Thus, activation of self
reactive T cells is likely to be regulated by additional signals.
Natural killer cell receptors are possible signal molecules that ful®ll
this task. In this respect, we recently demonstrated the expression of
both activating as well as inhibitory killer receptors on tumor
in®ltrating lymphocytes (TIL) in melanoma (Vetter et al, 2000).
This observation as well as the recent description of the activating
killer receptor, NKG2D, expressed both on natural killer and T
cells together with the identi®cation of its ligands, MICA and
MICB (Bauer et al, 1999), prompted us to characterize their
contribution to cellular immunity against melanoma.
MATERIALS AND METHODS
Tumor samples Fresh tumor samples from 40 primary and 20
metastatic melanomas were obtained by surgical excision. The tumor was
divided into two parts. One of these was snap frozen in liquid nitrogen
immediately after surgery and stored at ±80°C. The remaining part,
which included the thickest portion of the tumor, was used for routine
histology and diagnosis. Prior to any of these measures informed consent
was obtained from the patient.
Immunohistochemistry Five micrometer sections of tumor lesions
were ®xed in acetone and air dried for 30 min. Slides were incubated for
30 min with the indicated speci®c primary monoclonal antibody (MoAb)
at predetermined optimal dilutions ranging from 1:50 to 1:800. After
two washes slides were subjected to the biotinylated species speci®c
secondary MoAb (Dako, Hamburg, Germany) for 20 min, followed by
another two washes and an incubation in blocking solution. Next, slides
were stained with streptavidin±horseradish peroxidase and amino ethyl
carbazole-substrate. The reaction was stopped with double distilled water
after 25 min. Double staining slides were incubated with rabbit regular
serum at a ®nal dilution of 1:5 followed by the second primary MoAb,
speci®cally either CD3, T cell receptor (TCR)-g/d, CD25, CD28,
CD56, Vb2 TCR, Vb8 TCR, Vb12 TCR, Vb14 TCR or Vb17 TCR
(Immunotech, Hamburg, Germany; and Pharmingen, La Jolla, CA).
After a 40 min incubation and two washes, the species-speci®c secondary
antibodies were added and subsequent to additional two washing steps
visualization of bound antibodies with alkaline phosphatase-anti-alkaline
phosphatase and Fast Blue substrate was obtained. For single stainings,
slides were subjected to haÈmalaun nucleus staining. Antibodies to MICA
(6D4, murine IgG1) and NKG2-D (5C6, murine IgG2a) have been
described before (Groh et al, 1998, 1999; Bauer et al, 1999). All other
antibodies are commercially available and were used according to the
guidelines provided by the manufacturer.
TCR clonotypic mapping by denaturing gradient gel
electrophoresis (DGGE) DGGE clonotypic mapping of the human
TCR b variable (BV) regions 1±24 has been described in detail (thor
Straten et al, 1998). In short, RNA was isolated using the Pan RNA kit
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I (Pan Biotech GmbH, Aidenbach, Germany) and transcribed cDNA was
ampli®ed by polymerase chain reaction using speci®c primers for the
variable regions of all 24 TCR b-chain families. The computer program
MELT87 ensured that the ampli®ed DNA molecules were suited for
DGGE analysis if a 50 bp GC-rich sequence (GC-clamp) was attached to
the 5¢-end of the primer annealing to the constant region of the TCR
b-chain. DGGE analysis was done in 6% polyacrylamide gels containing
a gradient of urea and formamide from 20% to 80%. Electrophoresis was
performed at 160 V for 4.5 h in 1 3 tris acetate EDTA buffer at a
constant temperature of 54°C.
RESULTS
MIC expression in primary and metastatic
melanoma Expression of MICA/B in solid epithelial tumors
has been previously described (Groh et al, 1999). Here, we tested
for the expression of these MHC class I homologs in both primary
and metastatic cutaneous melanoma using the MoAb 6D4, which
binds to the a1a2 domain of this molecule. The detailed
information on the investigated primary tumors is given in
Table I. To this end, we detected reactivity with MoAb 6D4 in
31 of 40 primary tumors. The staining pattern, however, showed
substantial variations regarding intensity and frequency. In 15
primary tumors, the majority of tumor cells showed a strong and
homogeneous MIC expression, as depicted in Fig 1(A). The
second set of tumors was characterized by a strong staining of only a
subgroup of tumor cells (Fig 1B). These cells were not localized in
clusters but found isolated throughout the tumor suggesting a
regulated expression of MIC. The third group of tumors were
characterized by a few cells only weakly expressing MIC (Fig 1C).
Finally, in nine of the 40 investigated primary tumors no MIC
expressing cells were detectable by means of immuno-
histochemistry. It should be noted that neither the frequency nor
the intensity of MIC expression correlated with the degree of
invasion, i.e., the Breslow thickness (Fig 2). As none of the benign
melanocytic lesions analyzed for MIC expression (n = 10) were
tested positive (data not shown), it seems more likely that MIC
expression is associated with the initial neoplastic transformation
than with subsequent tumor progression.
For metastatic lesions, expression of MIC on tumor cells was
present in 13 of 20 analyzed samples (Fig 3A, B). Despite the fact
that the staining intensity still showed substantial variations among
different lesions, the staining pattern was more homogeneous than
in primary tumors in a sense that the intralesional variation was less
pronounced. Although a longitudinal analysis of MIC expression
Table I. MIC expression on primary melanoma
Gender Agea Type
Breslow
thicknessc
MIC
frequencyd
A/B
intensitye
NKG2-D
frequency f
F 31 SSMb 1.1 ++ ++ ++
F 28 SSM 2.0 ++ ++ +
M 76 SSM 1.1 + + ++
F 66 SSM 1.1 + + ++
M 65 NMM 2.0 + ++ +
M 94 LMM 1.1 + + (+)
M 78 LMM 0.3 + + ++
M 49 SSM 1.2 + ++ ++
F 65 SSM 3.0 + ++ ++
M 78 SSM 1.2 +++ ++ ++
M 69 SSM 2.1 + ++ +
F 36 NMM 3.0 ++ + +
F 65 NMM 1.2 +++ ++ + ++
M 58 SSM 1.3 é +
F 47 SSM 1.3 + + ++
F 45 SSM 2.2 é ++
M 44 NMM 2.2 ++ ++ + +
M 67 SSM 0.5 + ++ + ++ +
M 62 SSM 1.4 + ++ ++ +
M 49 SSM 0.5 + ++ +
F 64 NMM 2.3 é é
M 55 NMM 1.4 ++ ++ +
M 88 SSM 4.2 + ++ + ++ +
F 93 LMM 6.0 é é
F 58 LMM 0.6 + + +
M 73 NMM 3.3 ++ + ++ + ++
M 62 SSM 2.4 é é
F 30 SSM 1.6 é ++
M 60 SSM 1.6 + ++ + ++
M 50 SSM 0.7 + ++ + ++
F 21 SSM 2.5 é (+)
M 50 SSM 1.7 ++ ++ + ++
F 38 SSM 1.8 é é
F 66 SSM 0.9 + ++ + ++
F 65 SSM 3.6 + ++ ++
F 51 NMM 0.9 ++ ++ +
M 65 NMM 2.8 é (+)
M 71 SSM 3.8 + + +
M 64 SSM 3.8 + + +
M 58 SSM 3.8 + ++ + +
aAge of the patients at time of diagnosis in years.
bAbbreviations used: SSM, super®cial spreading melanoma; NMM, nodular ma-
lignant melanoma; LMM, lentigo maligna melanoma
cBreslow thickness is given in millimeters.
dThe number of melanoma cells stained with the MoAb 6D4 was classi®ed as
é, none; +, less than 25%; ++, between 25 and 75%; ++ +, more than 75%.
eThe intensity of the staining with 6D4 was graded as +, dim; ++, intermediate;
++ +, bright.
fThe number of TIL stained with MoAb 5C6 was classi®ed as é, none; (+) less
than 0.5%; +, between 0.5 and 5%; between 5 and 10%; ++ +, more than 10%.
The total number of stained TIL never exceeded 20%.
Figure 1. MIC expression in primary melanoma. Tumor tissue
from primary melanoma was obtained by surgical excisions, snap frozen
in liquid nitrogen, ®xed in acetone, and subjected to staining with the
anti-MIC monoclonal antibody 6D4. Positive cells are visualized by a
red color. (A±C) Exemplify the different staining patterns observed. Scale
bars: 50 mm.
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could only be performed in a subgroup of patients, it became
obvious that there was no correlation between MIC expression in
the primary tumor and the subsequently evolving metastasis.
Expression of NKG2-D on TIL The receptor for MIC
expressed on natural killer and T cells has been identi®ed as
NKG2-D (Bauer et al, 1999). Although its name suggests that this
receptor belongs to the CD94/NKG2 family, it neither forms a
heterodimer with CD94, mediates inhibitory signals, nor reacts
with HLA-E. As exemplary depicted in Fig 4 and summarized in
Table I, we observed expression of NKG2-D on TIL in most of
the analyzed primary tumors, i.e., 36 of 40 samples. Subsequent
detailed immunohistochemical analyses by double staining revealed
that these NKG2-D expressing TIL belonged to all lymphocyte
populations for which NKG2-D expression has previously been
described, i.e., ab and gd T cells as well as natural killer cells
(Figs 4C, E, F). The majority of NKG2-D expressing cells were
recruited from the a/b T cell pool in®ltrating the tumor, which,
however, dominated the TIL population anyhow. It should be
noted that skin in®ltrating CD3+ lymphocytes under various
in¯ammatory conditions, e.g., eczema, lichen planus, bullous
pemphigoid, as well as those present in normal skin also express
NKG2-D more frequently than CD3+ T cells in the peripheral
blood of the same individuals (data not shown). Thus, the skin
seems to be a compartment with a relative overexpression of
NKG2D similar to the intestine.1 Nevertheless, linear regression
Figure 2. Lack of correlation of Breslow thickness and MIC expression. Linear regression analysis of Breslow thickness and the incidence (A) or
the intensity (B) of MIC expression in primary melanoma shows no correlation.
1Lee L, Roberts A, Geraghty DE, et al: Isotypes of the NKG2 family of
NK receptors tightly regulate the function of intestinal ab T lymphocytes.
In: Keystone Symposium J3, Interfaces Between Innate and Adaptive Immunity,
2001 (abstr.)
Figure 3. MIC and NKG2-D expression in
metastatic lesions. Tissue from metastatic
melanoma was obtained by surgical excisions, snap
frozen in liquid nitrogen, ®xed in acetone, and
subjected to staining with either an anti-MIC
monoclonal antibody (A, B) or an anti-NKG2D
monoclonal antibody (clone 5C6; C, D). Positive
cells are visualized by a red color. Scale bars:
50 mm (A, C) and 25 mm (B, D)
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analysis of MIC and NKG2-D expression in metastatic lesions, as
depicted in Fig 5, revealed that the expression of these molecules
was positively correlated (p < 0.05); however, this result has to be
viewed with some caution due to the small sample size.
Expression of NKG2-D on clonally expanded T
cells Several lines of evidence suggest that only a fraction of
the in¯ammatory in®ltrate within and around melanoma is indeed
tumor reactive (thor Straten et al, 1999). As in situ staining using
tetrameric MHC/peptide complexes has only been established in
the murine system or on life sections (Skinner et al, 2000), we used
an indirect method to analyze for NKG2-D expression on tumor
reactive T cells. This approach is based on the assumption that T
cells are activated after interaction with their speci®c antigens and
subsequently will undergo clonal expansion (Becker and thor
Straten, 2000). Thus, primary tumors were analyzed for the
presence clonally expanded T cells among TIL by quantitative
TCR receptor usage analysis and subsequent reverse transcription±
polymerase chain reaction/DGGE based clonotype mapping for
the respective overexpressed TCR BV families. A representative
example for such an analysis is given for TCR BV8 in Fig 6. This
information was subsequently used to stain for these TCR BV
families used by the tracked overexpressed T cell clonotypes
(n = 6). Double staining with NKG2D revealed that the majority
of T cells expressing these TCR BV clonotypes indeed expressed
NKG2D (Fig 4D). In contrast, staining for several other TCR BV
families for whom no clonal expansion could be detected revealed
that only a portion of these cells were double positive with a range
from 40 to 60% (data not shown).
Characterization of NKG2D+ TIL The transition of T cells
from early activation, effector function to patrolling memory
cells is associated with characteristic changes in their phenotype.
We recently reported the preferential expression of CD28 on
Figure 4. Expression of NKG2-D on TIL.
Tumor tissue from primary melanoma was
obtained by surgical excisions, snap frozen in
liquid nitrogen, ®xed in acetone, and subjected to
either staining with an anti-NKG2D antibody
alone (A, B) or to double staining with
monoclonal antibodies against NKG2D together
with CD3 (C), TCR Vb8 (D), TCRgd (E),
CD56 (F), CD28 (G), or CD25 (H).Staining with
NKG2D antibodies are visualized by a red color,
staining with any of the others by a blue color,
and double stained cells appear purple (indicated
by closed arrowheads). Scale bars: 50 mm (A, B) and
25 mm (C±H).
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individual clonotypes present in the draining lymph nodes of
primary melanomas, but not on the respective clonotypes in the
tumor itself where these cells showed a low expression intensity
for this co-stimulating receptor (Becker et al, 2000). In this
regard, NKG2D+ cells among TIL showed a heterogeneous
expression of CD28. Double staining of primary tumors
revealed that these cells were both CD28 high and low
(Fig 4G). A comparable staining pattern was observed for
CD25, the a-chain of the interleukin-2 receptor that forms
together with the b- and g-chain the high-af®nity receptor for
interleukin-2. The expression of this activation marker on
NKG2D+ cells was not homogeneous, either (Fig 4H). These
observations indicate that NKG2D expression can be associated
with an activated effector state but is not necessarily. Future
analysis taking advantage of in situ tetramer staining will disclose
if this differential expression of activation markers is correlated
with antigen reactivity of the respective cells.
DISCUSSION
Cytotoxic lymphocytesÐregardless whether they belong to the
adaptive or the innate immune systemÐhave the vital function of
monitoring the cells of the body and eliminating any cell that may
be harmful to the host, e.g., after viral infection or neoplastic
transformation. For this task they are harnessed with a set of
receptors allowing recognition of target cells. T cell killing relies
primarily upon antigen receptors recognizing peptide epitopes
presented in the context of MHC class I molecules (Davis et al,
1998), whereas the receptor system used by innate effector cells is
less categorical; natural killer cell killing is regulated by the balance
between positive signals generated by engagement of activating
receptors and negative signals from inhibitory receptors (Lanier,
1998; Diefenbach and Raulet, 1999). This is likely to re¯ect a
substantial difference between the recognition strategies used by T
cells, which are relatively single-minded, and natural killer cells,
which use many different types of stimulatory receptors. Over the
past years, however, it became obvious that T cells may utilize the
same receptors as natural killer cells to ®ne tune their reactivity
(Lanier, 1998).
Herein, we studied the expression of the activating killer
receptor NKG2D in immune responses to melanoma. Accordingly,
we ®rst established whether a ligand for NKG2D would be
expressed on melanoma cells. To this end, immunohistochemistry
of both primary and metastatic melanoma lesions revealed that MIC
was indeed present on the majority of analyzed samples. NKG2D in
turn was present on a subset of TIL that included ab and gd T cells
as well as natural killer cells. Moreover, indirect evidence, i.e., the
expression of NKG2D on clonally expanded cells, suggests that this
receptor may be indeed involved in the regulation of immune
responses to melanoma. It has recently been demonstrated that
engagement of NKG2D serves as a costimulating function for
virus-speci®c CD8 ab T cells, gd T cells as well as natural killer
cells (Das et al, 2001; Groh et al, 2001; Pende et al, 2001).
Engagement of NKG2D potently augmented TCR-dependent
cytolytic and cytokine responses by cytomegalovirus-speci®c
CD28± T cells. Moreover, this function overcame viral interference
with MHC class I antigen presentation (Groh et al, 2001). Thus,
NKG2D may function as a costimulatory receptor that allows to
reconstitute speci®c T cell responses even after downregulation of
MHC class I molecules. The latter has been suggested as an
effective immune escape mechanism of melanoma (Marincola et al,
2000). Yet, the detailed mechanisms how NKG2D expression is
regulated remain elusive. In the murine system, several lines of
evidence suggest that NKG2D expression may be induced by T cell
activation (Diefenbach et al, 2000). Our ®nding that NKG2D is
expressed with a higher frequency on clonally expanded than on
nonoverexpressed T cells corroborates with this notion.
The mechanism by which NKG2D signals has not been entirely
determined. Similar to other activating natural killer cell receptors,
NKG2D contains a positive charge in its transmembrane domain
that promotes interactions with acidic residues in the transmem-
brane domains of adaptor proteins, i.e., DAP10 (Wu et al, 1999).
This adaptor protein maps to chromosome 19q13.1. In difference
to most other adaptor proteins its cytoplasmic domain seems not to
contain an ITAM, but instead contains an SH2-binding YxxM
motif that appears to recruit the p85 catalytic subunit of
phosphatidylinositol (PI) 3-kinase (Wu et al, 2000). Interestingly,
the T cell costimulatory molecule CD28 contains an akin motif
suggesting the possibility that NKG2D and TCR mediated signals
are also integrated on the transcriptional level to ensure T cell
activation.
One of the best characterized family of ligands for NKG2D is the
MIC family. These nonclassical MHC class I molecules are
encoded by genes located near to the locus for the human MHC
class I molecule HLA-B (Bahram and Spies, 1996). Unlike most
MHC class I molecules, MIC is not associated with b2-
microglobulin and does not bind peptide. MIC expression is
substantially upregulated on many epithelial tumors (Groh et al,
1999) and, as presented here, on melanoma. These ®ndings suggest
that MIC molecules could play an important part in the immune
surveillance of transformed cells.
Figure 5. Correlation of MICA and NKG2-D expression. Linear
regression analysis of MIC and NKG2-D expression in metastatic lesions
shows positive correlation (p < 0.05).
Figure 6. Clonotypic analysis for TCR BV8 of TIL in melanoma.
TCR clonotype mapping based on reverse transcription±polymerase
chain reaction/DGGE for TCR BV8. The expression intensity for each
clone was measured using TotalLab (TotalLab, Biostat, Jahnsdorf,
Germany) software.
604 VETTER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
The MIC gene transcriptional regulatory sequences contain
heat-shock elements similar to those in the human Hsp70
promoter. As genotoxic chemotherapeutic agents activate the
Hsp70 promoter via binding of HSF-1 and induce thereby gene
transcription (Liu et al, 1996) MIC expression might be upregulated
by such a mechanism. This notion is of particular interest as it may
link chemotherapy and immunotherapy and explains the synergistic
effects of these different therapeutic approaches observed clinically,
especially the observation that chemotherapy should precede the
immunomodulation to ensure the best therapeutic effect (Legha,
1997). Thus, MIC expression could be the ¯ag raised on tumor
cells by these measures to recruit and/or activate tumor-speci®c
lymphocytes.
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